Serina Therapeutics appoints Dr. Srini Tenjarla as SVP of CMC and Formulation

Serina Therapeutics, Inc.

Tenjarla joins from Takeda, where he was VP and Head of Drug Product Development.
At Takeda he oversaw phase-appropriate development from Phase 1 through validation.
Previously held leadership roles at Shire, including VP of Pharmaceutical Sciences.
He holds a Ph.D. in Pharmaceutical Sciences from the University of Houston.
Appointment effective July 15, 2024; will oversee CMC activities across pipeline.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Srini Tenjarla

Senior Vice President, CMC & Formulation

SER · Serina Therapeutics, Inc.

Effective: 2024-07-15
Filed: July 18, 2024, 7:59 PM ET

On July 18, 2024, Serina Therapeutics, Inc. (the “ Company ”) announced the hiring of Dr. Srini Tenjarla as Senior Vice President, CMC & Formulation.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Srini Tenjarla was appointed as Senior Vice President, CMC & Formulation at Serina Therapeutics, Inc..

Action: appointed
Role: Senior Vice President, CMC & Formulation

Exact text from the filing

On July 18, 2024, Serina Therapeutics, Inc. (the “ Company ”) announced the hiring of Dr. Srini Tenjarla as Senior Vice President, CMC & Formulation.

View on SEC.gov

Serina Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-028363

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.